Table 2.
Laboratory parameters monitored for TLS per Howard criteria in patients who completed ibrutinib lead-in and started ibrutinib plus venetoclax.
| MRD cohort | FD cohort | Pooled cohorts | ||||
|---|---|---|---|---|---|---|
| N = 159 | N = 153 | N = 312 | ||||
| Met Howard criteria, n (%) | Before venetoclaxa | After venetoclaxb | Before venetoclaxa | After venetoclaxb | Before venetoclaxa | After venetoclaxb |
| Uric acid >475.8 μmol/L | 3 (2) | 9 (6) | 0 | 7 (5) | 3 (1) | 16 (5) |
| Phosphorous >1.5 mmol/L | 6 (4) | 40 (25) | 6 (4) | 37 (24) | 12 (4) | 77 (25) |
| Potassium >6.0 mmol/L | 0 | 1 (0.6) | 1 (0.7) | 3 (2) | 1 (0.3) | 4 (1) |
| Corrected calcium <1.75 mmol/L | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine increased by ≥26.5 μmol/Ld | NA | 6 (4) | NA | 5 (3) | NA | 11 (3) |
| Laboratory TLSc | 0 | 1 (0.6) | 0 | 0 | 0 | 1 (0.3) |
| Laboratory TLS with increased creatinined,e | NA | 0 | NA | 0 | NA | 0 |
Abbreviations: FD, fixed duration; MRD, minimal residual disease; NA, not applicable; TLS, tumor lysis syndrome.
aLast measurement before initiation of venetoclax.
bWithin 8 weeks after the first dose of venetoclax.
cPresence of ≥2 metabolic abnormalities within the same 24-hour period.
dCreatinine increased by ≥26.5 μmol/L since last measurement before initiation of venetoclax.
eCreatinine increased by ≥26.5 μmol/L within 24 hours of laboratory TLS.